Gain of chromosome X in prostatic atrophy detected by CGH and FISH analyses

Prostate

Volumn 67, Issue 4, 2007, Pages 433-438

  Yildiz Sezer, Seval ^a   Verdorfer, Irmgard ^a   Schäfer, Georg ^a   Rogatsch, Hermann ^a,b   Bartsch, Georg ^c   Mikuz, Gregor ^a  

^a MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Chromosome X; Comparative genomic hybridization; Fluorescence in situ hybridization; Proliferative inflammatory atrophy; Prostate cancer

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; ATROPHY; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; X CHROMOSOME; X CHROMOSOME ABERRATION;

ADULT; AGED; ATROPHY; CHROMOSOMES, HUMAN, X; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEX CHROMOSOME ABERRATIONS;

EID: 33847345929     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20535     Document Type: Article

References (38)

1. Karan D, Lin MF, Johansson SL, Batra SK. Current status of molecular genetics of human prostatic adenocarcinomas. Int J Cancer 2003;103:285-293.
2. Schwab M, Amler LC. Amplification of cellular oncogenes: A predictor of clinical outcome in human cancer. Genes Chromosomes Cancer 1990;1:181-193.
3. Matsuda K, Matsuyama H, Hara T, Yoshihiro S, Oga A, Kawauchi S, Furuya T, Izumi H, Naito K, Sasaki K. DNA sequence copy number aberrations in prostate cancers: A comparison of comparative genomic hybridization data between Japan and European countries. Cancer Genet Cytogenet 2004;152:119-123.
4. Strohmeyer DM, Berger AP, Moore DH II, Bartsch G, Klocker H, Carroll PR, Loening SA, Jensen RH. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: Association with progression and angiogenesis. Prostate 2004;59:43-58.
5. Kim SH, Kim MS, Jensen RH. Genetic alterations in microdissected prostate cancer cells by comparative genomic hybridization. Prostate Cancer Prostatic Dis 2000;3:110-114.
6. Fu W, Bubendorf L, Willi N, Moch H, Mihatsch MJ, Sauter G, Gasser TC. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. Urology 2000;56:880-885.
7. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000;80:931-942.
8. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-148.
9. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-347.
10. Gburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol 1997;157:223-227.
11. Ropke A, Erbersdobler A, Hammerer P, Palisaar J, John K, Stumm M, Wieacker P. Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Prostate 2004;59:59-68.
12. Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 1999;189:219-223.
13. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002;198:237-244.
14. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate cancer. J Natl Cancer Inst 1999;91:1574-1580.
15. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-531.
16. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002;15:35-44.
17. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, Baretton GB. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000;80:1455-1464.
18. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, Bauchinger M, Werner M. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001;84:202-208.
19. Nelson WG, De Marzo AM, Isaacs W. Prostate cancer. N Engl J Med 2003;349:366-381.
20. Mc Neal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-633.
21. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998;22:1073-1077.
22. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
23. Billis A. Prostatic atrophy: An autopsy study of a histologic mimic of adenocarcinoma. Mod Pathol 1998;11:47-54.
24. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-832.
25. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic hyperplasia of the prostate in Japan: Histologic and immunohistochemical features and p53 gene mutation analysis. Prostate 2002;52:279-287.
26. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am J Pathol 2003;163:923-933.
27. Macoska JA, Trybus TM, Wojno KJ. 8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 2000;55:776-782.
28. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: Neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-1773.
29. Yildiz-Sezer S, Verdorfer I, Schäfer G, Rogatsch H, Bartsch G, Mikuz G. Assessment of aberrations on chromosome 8 in prostatic atrophy. BJU Inter 2006;98:184-188.
30. Wolff E, Liehr T, Vorderwülbecke U, Tulusan AH, Husslein EM, Gebhart E. Frequent gains and losses of specific chromosome segments in human ovarian carcinomas shown by comparative genomic hybridization. Int J Oncol 1997;11:19-23.
31. Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T, Gonzalez M, Sangan T, Earl H, Caldas C. A simple and reliable pretreatment protocol facilities fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. J Clin Mol Pathol 2003;56:275-279.
32. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-3015.
33. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555.
34. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Gronberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175-179.
35. Iavarone C, Wolfgang C, Kumar V, Duray P, Willingham M, Pastan I, Bera TK. PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in prostate cancers. Mol Cancer Ther 2002;1:329-335.
36. Postma R, Schroder FH, van der Kwast TH. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 2005;65:745-749.
37. Franks LM. Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 1954;68:617-621.
38. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine S, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montirorti R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJLH, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A Working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-1291.